The Future of Drug Design
Bob Bradway
I’m excited to be leading Amgen as we harness dramatic advances in science and technology to serve patients suffering from serious diseases.
Over the past several decades, companies like Amgen have dramatically advanced human health despite being able to attack only a small percentage of disease-causing molecular targets. Today, though, we stand at the dawn of a new era of innovation in drug design that promises to transform our basic ideas about how drugs can work, vastly expand the universe of “druggable” targets, and make possible many new treatments for many more diseases.
To learn more about these remarkable developments, I invite you to join Amgen later today for our first-ever “LinkedIn Live” event featuring two members of the National Academy of Sciences: Ray Deshaies, Amgen’s Senior Vice President of Global Research, and Stanford University chemistry professor Carolyn Bertozzi.
The event kicks off Monday, October 5, at 4:00 pm Pacific Time / 7:00 pm Eastern Time on Amgen’s LinkedIn page. If you are unable to join us live, a recording of the conversation will be available following the event.
I hope to see you there!
#mycompany #wearebiotech